Literature DB >> 26378639

Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification.

Alastair D Burt1, Carolin Lackner2, Dina G Tiniakos3.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of clinical and histopathological changes including "simple" steatosis, steatosis with inflammation, steatohepatitis, cirrhosis, and hepatocellular carcinoma. It was initially described in the context of drug-induced liver injury and acute liver disease following jejunoileal bypass surgery, but since the early 1980s it has been widely acknowledged as the hepatic manifestation of metabolic syndrome. It now represents a burgeoning public health crisis and is fast becoming the main indication for liver transplantation in some parts of the world. Its true incidence and prevalence are unknown, although estimates have been made from large imaging studies. Liver biopsy interpretation is still regarded as the gold standard for making accurate diagnoses in NAFLD, but sampling limitations are recognized. Furthermore, clear definitions for key histopathological components have been lacking, resulting in significant interobserver variations in making a diagnosis of steatohepatitis. In this review the authors consider some aspects of classification and variant forms of NAFLD such as that occurring in children. They provide an update on grading and staging systems and histopathological prognostic factors, and address the role of liver biopsy in contemporary clinical care of patients with NAFLD. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2015        PMID: 26378639     DOI: 10.1055/s-0035-1562942

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  28 in total

Review 1.  Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either.

Authors:  Phillipp Hartmann; Huikuan Chu; Yi Duan; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-02-15       Impact factor: 4.052

2.  Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates.

Authors:  Leigh Goedeke; Liang Peng; Valle Montalvo-Romeral; Gina M Butrico; Sylvie Dufour; Xian-Man Zhang; Rachel J Perry; Gary W Cline; Paul Kievit; Keefe Chng; Kitt Falk Petersen; Gerald I Shulman
Journal:  Sci Transl Med       Date:  2019-10-02       Impact factor: 17.956

3.  miR-122-5p/KIF5B/AMPK/AKT regulatory network regulates the progression of NAFLD.

Authors:  Jianling Zhang; Huanjun Huang
Journal:  Am J Transl Res       Date:  2021-02-15       Impact factor: 4.060

Review 4.  Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review.

Authors:  Getnet Teshome; Sintayehu Ambachew; Alebachew Fasil; Molla Abebe
Journal:  Hepat Med       Date:  2020-09-24

Review 5.  A review on the effect of gut microbiota on metabolic diseases.

Authors:  Qiwei Shi; Lingli Dai; Qi Zhao; Xian Zhang
Journal:  Arch Microbiol       Date:  2022-02-23       Impact factor: 2.552

Review 6.  Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance.

Authors:  Paul D Berk; Elizabeth C Verna
Journal:  Clin Liver Dis       Date:  2016-02-18       Impact factor: 6.126

Review 7.  Innate Immunity and Inflammation in NAFLD/NASH.

Authors:  Marco Arrese; Daniel Cabrera; Alexis M Kalergis; Ariel E Feldstein
Journal:  Dig Dis Sci       Date:  2016-02-03       Impact factor: 3.199

Review 8.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

9.  The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis.

Authors:  Guiqiang Wang; Atsushi Tanaka; Hong Zhao; Jidong Jia; Xiong Ma; Kenichi Harada; Fu-Sheng Wang; Lai Wei; Qixia Wang; Ying Sun; Yuan Hong; Huiying Rao; Cumali Efe; George Lau; Diana Payawal; Rino Gani; Keith Lindor; Wasim Jafri; Masao Omata; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-05-04       Impact factor: 6.047

Review 10.  Pathology of non-alcoholic fatty liver disease.

Authors:  Ivana Cataldo; Samantha Sarcognato; Diana Sacchi; Matilde Cacciatore; Francesca Baciorri; Alessandra Mangia; Nora Cazzagon; Maria Guido
Journal:  Pathologica       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.